Melinta Therapeutics, Inc. Common Stock
MLNT
MLNT was delisted on the 10th of January, 2020.
52 hedge funds and large institutions have $18.6M invested in Melinta Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 29 closing their positions.
17% more call options, than puts
Call options by funds: $254K | Put options by funds: $217K
0% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 19
31% less capital invested
Capital invested by funds: $26.9M → $18.6M (-$8.34M)
32% less funds holding
Funds holding: 77 → 52 (-25)
86% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 29
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$1.57M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$905K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$832K |
| 4 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$829K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$445K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OH
Oikos Holdings
New York
|
-$13.2M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.28M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$782K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$769K |
| 5 |
First Manhattan
New York
|
-$749K |
MLNT Hedge Fund Activity: Q1 2019 in Review
52 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q1 2019, worth a combined $18.6M — down 31% from $26.9M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of MLNT and 4 opened new positions — a net loss of 25 holders — while 19 trimmed existing stakes and 19 added.
The largest buyer was Deerfield Management, adding an estimated $1.57M. The largest seller was Oikos Holdings, exiting entirely with an estimated $13.2M sold.
- 52 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q1 2019, down from 77 in Q4 2018.
- Funds reported $18.6M of Melinta Therapeutics, Inc. Common Stock stock for Q1 2019, down 31% quarter-over-quarter.
- 4 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q1 2019 and 29 closed out, a net change of -25 holders.
- The largest Melinta Therapeutics, Inc. Common Stock buyer in Q1 2019 was Deerfield Management, an estimated $1.57M added.
- The largest Melinta Therapeutics, Inc. Common Stock seller in Q1 2019 was Oikos Holdings, an estimated $13.2M sold.
Based on aggregated 13F filings for Q1 2019.